Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
Entity
UAM. Departamento de Ingeniería InformáticaPublisher
BioMed Central Ltd.Date
2010-09-01Citation
10.1186/bcr2633
Breast Cancer Research 12.5 (2010): R66
ISSN
1465-5411 (print); 1465-542X (online)DOI
10.1186/bcr2633Funded by
This work was supported by a grant from the Susan G Komen Foundation (to YK).Editor's Version
http://breast-cancer-research.com/content/12/5/R66Subjects
InformáticaRights
© 2010 Parisi et al.; license BioMed Central Ltd.Abstract
Introduction: Multi-marker molecular assays have impacted management of early stage breast cancer, facilitating adjuvant chemotherapy decisions. We generated prognostic models that incorporate protein-based molecular markers and clinico-pathological variables to improve survival prediction.
Methods: We used a quantitative immunofluorescence method to study protein expression of 14 markers included in the Oncotype DX™ assay on a 638 breast cancer patient cohort with 15-year follow-up. We performed cross-validation analyses to assess performance of multivariate Cox models consisting of these markers and standard clinico-pathological covariates, using an average time-dependent Area Under the Receiver Operating Characteristic curves and compared it to nested Cox models obtained by robust backward selection procedures.
Results: A prognostic index derived from of a multivariate Cox regression model incorporating molecular and clinico-pathological covariates (nodal status, tumor size, nuclear grade, and age) is superior to models based on molecular studies alone or clinico-pathological covariates alone. Performance of this composite model can be further improved using feature selection techniques to prune variables. When stratifying patients by Nottingham Prognostic Index (NPI), the most prognostic markers in high and low NPI groups differed. Similarly, for the node-negative, hormone receptor-positive sub-population, we derived a compact model with three clinico-pathological variables and two protein markers that was superior to the full model.
Conclusions: Prognostic models that include both molecular and clinico-pathological covariates can be more accurate than models based on either set of features alone. Furthermore, feature selection can decrease the number of molecular variables needed to predict outcome, potentially resulting in less expensive assays.
Files in this item
Google Scholar:Parisi, Fabio
-
González, Ana M.
-
Nadler, Yasmine
-
Camp, Robert L.
-
Rimm, David L.
-
Kluger, Harriet M.
-
Kluger, Yuval
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Deregulated microRNAs in breast cancer and their potential role as diagnostic and prognostic biomarkers
Matamala Zamarro, Nerea
2015-05-27